Related references
Note: Only part of the references are listed.Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: A systematic review and network meta-analysis
E. L. Simpson et al.
BONE (2020)
Efficacy and safety of denosumab compared to bisphosphonates in improving bone strength in postmenopausal osteoporosis: a systematic review
Thulasi Chandran et al.
SINGAPORE MEDICAL JOURNAL (2019)
Comparative efficacy and safety of pharmacological interventions for osteoporosis in postmenopausal women: a network meta-analysis (Chongqing, China)
Xiang Tan et al.
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY (2019)
Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis
J. -Y. Reginster et al.
OSTEOPOROSIS INTERNATIONAL (2019)
Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab
D. L. Kendler et al.
OSTEOPOROSIS INTERNATIONAL (2019)
One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study
E. Michael Lewiecki et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2019)
Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis
Athanasios D. Anastasilakis et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2018)
Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study
Michael R. McClung et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial
Bente L. Langdahl et al.
LANCET (2017)
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
Kenneth G. Saag et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study
Bo-cheng Liang et al.
ORTHOPAEDIC SURGERY (2017)
Six Weeks of Daily Abaloparatide Treatment Increased Vertebral and Femoral Bone Mineral Density, Microarchitecture and Strength in Ovariectomized Osteopenic Rats
Hila Bahar et al.
CALCIFIED TISSUE INTERNATIONAL (2016)
Network Meta-Analysis of Pharmacological Agents for Osteoporosis Treatment and Fracture Prevention
Xu-cheng Yang et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2016)
Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
P. D. Miller et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
F. Cosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
Brian Hutton et al.
ANNALS OF INTERNAL MEDICINE (2015)
Denosumab for the treatment of osteoporosis
Sarah Zaheer et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2015)
The Effect of 6 Versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT)
Dennis M. Black et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
Treatment Satisfaction in Postmenopausal Women Suboptimally Adherent to Bisphosphonates Who Transitioned to Denosumab Compared With Risedronate or Ibandronate
Santiago Palacios et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial
Benjamin Z. Leder et al.
LANCET (2015)
The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study
S. Papapoulos et al.
OSTEOPOROSIS INTERNATIONAL (2015)
Denosumab versus zoledronic acid in patients previously treated with zoledronic acid
A. D. Anastasilakis et al.
OSTEOPOROSIS INTERNATIONAL (2015)
Efficacy and Safety of Single-Dose Zoledronic Acid for Osteoporosis in Frail Elderly Women A Randomized Clinical Trial
Susan L. Greenspan et al.
JAMA INTERNAL MEDICINE (2015)
Differing effects of denosumab and alendronate on cortical and trabecular bone
Roger M. Zebaze et al.
BONE (2014)
Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: Efficacy and safety results from a randomized open-label study
C. Roux et al.
BONE (2014)
Effects of intravenous zoledronate and ibandronate on carotid intima-media thickness, lipids and FGF-23 in postmenopausal osteoporotic women
S. Gonnelli et al.
BONE (2014)
Two Years of Denosumab and Teriparatide Administration in Postmenopausal Women With Osteoporosis (The DATA Extension Study): A Randomized Controlled Trial
Benjamin Z. Leder et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Cortical bone loss at the tibia in postmenopausal women with osteoporosis is associated with incident non-vertebral fractures: Results of a randomized controlled ancillary study of HORIZON
A. W. Popp et al.
MATURITAS (2014)
Influence of patient perceptions and preferences for osteoporosis medication on adherence behavior in the Denosumab Adherence Preference Satisfaction study
David L. Kendler et al.
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY (2014)
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
Michael R. McClung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate
J. P. Brown et al.
OSTEOPOROSIS INTERNATIONAL (2014)
Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study
M. A. Paggiosi et al.
OSTEOPOROSIS INTERNATIONAL (2014)
Challenges in implementing and maintaining osteoporosis therapy
Ankita Modi et al.
INTERNATIONAL JOURNAL OF WOMENS HEALTH (2014)
Randomized Trial Comparing Monthly Ibandronate and Weekly Alendronate for Osteoporosis in Patients With Primary Biliary Cirrhosis
Nuria Guanabens et al.
HEPATOLOGY (2013)
Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial
Joy N. Tsai et al.
LANCET (2013)
Denosumab Compared With Ibandronate in Postmenopausal Women Previously Treated With Bisphosphonate Therapy A Randomized Open-Label Trial
Chris Recknor et al.
OBSTETRICS AND GYNECOLOGY (2013)
Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension
Socrates Papapoulos et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)
Dennis M. Black et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Low-Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized Controlled Trial
Andrew Grey et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis
J-Y. Reginster et al.
OSTEOPOROSIS INTERNATIONAL (2012)
Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women Transitioning From Alendronate Therapy
David L. Kendler et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Microarchitectural Deterioration of Cortical and Trabecular Bone: Differing Effects of Denosumab and Alendronate
Ego Seeman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Long-term treatment of postmenopausal osteoporosis with strontium ranelate: Results at 8 years
J. Y. Reginster et al.
BONE (2009)
Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial
Jacques P. Brown et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal Women
Andrew Grey et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Zoledronic Acid for the Prevention of Bone Loss in Postmenopausal Women With Low Bone Mass A Randomized Controlled Trial
Michael McClung et al.
OBSTETRICS AND GYNECOLOGY (2009)
Cortical and trabecular architecture are altered in postmenopausal women with fractures
E. Sornay-Rendu et al.
OSTEOPOROSIS INTERNATIONAL (2009)
Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis
P. J. Meunier et al.
OSTEOPOROSIS INTERNATIONAL (2009)
被撤回的出版物: Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis (Retracted article. See vol. 59, pg. 167, 2018)
Jun Iwamoto et al.
YONSEI MEDICAL JOURNAL (2008)
Mechanisms of anabolic therapies for osteoporosis
Ernesto Canalis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Increases in BMD correlate with improvements in bone microarchitecture with Teriparatide treatment in postmenopausal women with osteoporosis
Peiqi Chen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Effects of continuing or stopping alendronate after 5 years of treatment - The Fracture Intervention Trial long-term extension (FLEX): A randomized trial
Dennis M. Black et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
The molecular mechanism of nitrogen-containing bisphosphonates as anti osteoporosis drugs
Kathryn L. Kavanagh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial
MJ Hooper et al.
CLIMACTERIC (2005)
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis
PJ Meunier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis
CH Chesnut et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial
H Morii et al.
OSTEOPOROSIS INTERNATIONAL (2003)
Recombinant human parathyroid hormone (1-34) [Teriparatide] improves both cortical and cancellous bone structure
YB Jiang et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
A Randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis
JJ Body et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
Daily oral pamidronate in women and men with osteoporosis: A 3-year randomized placebo-controlled clinical trial with a 2-year open extension
C Brumsen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2002)
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
RM Neer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
